Research and Training Grants in Prostate Cancer

Spotlight on Prostate Cancer Grantees

Following are some of the lung cancer investigators currently being funded by the American Cancer Society who are working to find the answers that will save more lives and better prevent, treat, and manage prostate cancer.

John Wilkinson, PhD

Wilkinson is studying how a protein called apoptosis-inducing factor (AIF) and its cellular partners work together to help prostate cancer cells grow. With this information, the hope is new drugs could be designed to more effectively target and kill prostate cancer cells.

Ilir Agalliu, MD, ScD

Agalliu is examining the complex role of insulin and insulin-like growth factors in aggressive prostate cancers. He is looking at the part they play in cancer progression and recurrence. Such insights could lead to biological markers that predict who’s at risk for aggressive prostate cancer and possibly targets for new drugs to prevent and treat the disease.

Andrew Hsieh, MD

Hsieh has discovered how a protein called mTOR goes haywire and helps prostate cancer cells grow and invade healthy tissues, a process called metastasis. Current mTOR inhibitors have been unable to fully block mTOR, so researchers are now testing experimental drugs to more completely stop mTOR from working.

Scott Dehm, PhD

Dehm is studying the changes that occur in the target of hormone therapy – the androgen receptor – that allow it to develop an intractable resistance to hormone-blocking drugs. The goal is to develop new hormone-targeted drugs that work better and longer to suppress prostate cancer growth.

Hong Xiao, PhD

African American men are 63% more likely to be diagnosed with prostate cancer compared to white men. They’re also more than twice as likely to die from the disease. Xiao is identifying and mapping the factors responsible for geographic and racial differences in the number of prostate cancer cases and deaths over a recent 25-year period in Florida. 

From Our Researchers

fill in here